Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Lifesci Capital

Lifesci Capital upgraded shares of Prime Medicine (NASDAQ:PRME) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.

A number of other equities analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Prime Medicine in a report on Monday, December 29th. Wall Street Zen cut Prime Medicine from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Prime Medicine Stock Performance

PRME stock opened at $4.23 on Monday. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.94. The business has a 50-day moving average price of $3.80. The firm has a market cap of $763.56 million, a PE ratio of -2.94 and a beta of 2.56.

Prime Medicine (NASDAQ:PRME) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.24) earnings per share (EPS) for the quarter. Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%. The firm had revenue of $0.84 million for the quarter.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.